Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) over the past three months, with a majority being bullish. The average 12-month price target has increased by 9.82% to $60.4. The company has shown significant revenue growth but faces challenges with ROE and ROA.
October 07, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals has received predominantly bullish ratings from analysts, with an increased average price target of $60.4. The company has shown strong revenue growth but struggles with ROE and ROA.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. However, financial metrics like ROE and ROA are below industry standards, which could temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100